Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Oncolytics Biotech ( (ONCY) ) is now available.
On April 6, 2026, Oncolytics Biotech announced it had scheduled a Type C meeting with the U.S. Food and Drug Administration for April 16, 2026, to discuss a potential single-arm registrational study of pelareorep plus a checkpoint inhibitor in second-line and later squamous cell anal carcinoma. The proposed pivotal trial would enroll about 60 to 70 patients who have exhausted approved therapies, using objective response rate as the primary endpoint to support a potential full approval in a setting with significant unmet medical need.
The company highlighted that pelareorep combined with a checkpoint inhibitor produced roughly a 30% objective response rate and a 17-month median duration of response in late-line SCAC patients in the GOBLET study, comparing favorably with real-world response rates of 10–14% and a 9.5-month median duration. Management framed the FDA discussion as a critical step toward a clearer and potentially more efficient approval pathway in a rare cancer where global incidence is about 54,000 cases annually and the anal cancer market is projected to roughly double to $2.3 billion between 2025 and 2035.
The most recent analyst rating on (ONCY) stock is a Hold with a $0.92 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
Spark’s Take on ONCY Stock
According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.
Overall score reflects weak financial fundamentals (no revenue, ongoing losses/cash burn and negative equity) and bearish technicals (below key moving averages with negative MACD). These are partially offset by favorable corporate events, including FDA Fast Track designation and continued clinical progress for pelareorep.
To see Spark’s full report on ONCY stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent designed to convert immunologically “cold” tumors “hot” by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic gastrointestinal cancers, including colorectal and pancreatic cancer where it has U.S. FDA Fast Track designation, and is seeking strategic partnerships to accelerate development and commercialization.
Pelareorep has shown encouraging results in multiple first-line pancreatic cancer trials, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer, positioning Oncolytics within the emerging immuno-oncology and oncolytic virus space. By targeting indications with significant unmet need and limited late-line options, the company is aiming to carve out a differentiated niche in the gastrointestinal cancer market.
Average Trading Volume: 1,370,262
Technical Sentiment Signal: Sell
Current Market Cap: $111.5M
For an in-depth examination of ONCY stock, go to TipRanks’ Overview page.